Difference between revisions of "Antiemesis"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (updated content)
Line 1: Line 1:
−
Adapted from the NCCN<ref>[http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf NCCN antiemesis guidelines version 1.2012]</ref> and ASCO guidelines.<ref>[http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Guidelines/Clinical+Practice+Guidelines/Antiemetics%3A+American+Society+of+Clinical+Oncology+Clinical+Practice+Guideline+Update Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update (2011)]</ref><ref>[http://www.asco.org/ASCOv2/Department%20Content/Cancer%20Policy%20and%20Clinical%20Affairs/Downloads/Guideline%20Tools%20and%20Resources/Antiemetics/2011/Antiemetics%20Full%20Guideline%2010.14.11.pdf ASCO 2011 antiemetics guideline PDF]</ref><ref>[http://www.asco.org/ASCOv2/Department%20Content/Cancer%20Policy%20and%20Clinical%20Affairs/Downloads/Guideline%20Tools%20and%20Resources/Antiemetics/2011/Antiemetic%20Dosing%20Clinical%20Tool_9.21.11.pdf ASCO 2011 antiemetics table]</ref>
+
Adapted from the NCCN<ref>[http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf NCCN antiemesis guidelines version 2.2014]</ref> and ASCO guidelines.<ref>[http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Guidelines/Clinical+Practice+Guidelines/Antiemetics%3A+American+Society+of+Clinical+Oncology+Clinical+Practice+Guideline+Update Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update (2011)]</ref><ref>[http://www.asco.org/ASCOv2/Department%20Content/Cancer%20Policy%20and%20Clinical%20Affairs/Downloads/Guideline%20Tools%20and%20Resources/Antiemetics/2011/Antiemetics%20Full%20Guideline%2010.14.11.pdf ASCO 2011 antiemetics guideline PDF]</ref><ref>[http://www.asco.org/ASCOv2/Department%20Content/Cancer%20Policy%20and%20Clinical%20Affairs/Downloads/Guideline%20Tools%20and%20Resources/Antiemetics/2011/Antiemetic%20Dosing%20Clinical%20Tool_9.21.11.pdf ASCO 2011 antiemetics table]</ref>
  
 
==Emetic risk of chemotherapy==
 
==Emetic risk of chemotherapy==
Line 18: Line 18:
 
!ASCO emetogenic potential
 
!ASCO emetogenic potential
 
!Comment
 
!Comment
 +
|-
 +
|align="left" | [[Ado-trastuzumab emtansine (Kadcyla)]]
 +
|Low
 +
|
 +
|
 
|-
 
|-
 
|align="left" | Anthracycline (see differences between NCCN & ASCO) & [[Cyclophosphamide (Cytoxan)]] combination chemotherapy
 
|align="left" | Anthracycline (see differences between NCCN & ASCO) & [[Cyclophosphamide (Cytoxan)]] combination chemotherapy
Line 25: Line 30:
 
|-
 
|-
 
|align="left" | [[Aldesleukin (Proleukin)]]  
 
|align="left" | [[Aldesleukin (Proleukin)]]  
−
|Moderate: >12-15 million international units/m2<br>Low: <=12 million international units/m2
+
|Moderate: >12 to 15 million international units/m2<br>Low: ≤12 million international units/m2
 
|
 
|
 
|
 
|
Line 40: Line 45:
 
|-
 
|-
 
|align="left" | [[Amifostine (Ethyol)]]  
 
|align="left" | [[Amifostine (Ethyol)]]  
−
|Moderate: >300 mg/m2<br>Low: <=300 mg
+
|Moderate: >300 mg/m2<br>Low: ≤300 mg
 
|
 
|
 
|
 
|
Line 51: Line 56:
 
|align="left" | [[Asparaginase (Elspar)]]
 
|align="left" | [[Asparaginase (Elspar)]]
 
|Minimal
 
|Minimal
 +
|
 +
|
 +
|-
 +
|align="left" | [[Axitinib (Inlyta)]] (oral)
 +
|Low/Minimal
 
|
 
|
 
|
 
|
Line 82: Line 92:
 
|Minimal
 
|Minimal
 
|Low
 
|Low
 +
|
 +
|-
 +
|align="left" | [[Bosutinib (Bosulif)]] (oral)
 +
|Low/Minimal
 +
|
 +
|
 +
|-
 +
|align="left" | [[Brentuximab vedotin (Adcetris)]]
 +
|Low
 +
|
 
|
 
|
 
|-
 
|-
 
|align="left" | [[Busulfan (Myleran)]]
 
|align="left" | [[Busulfan (Myleran)]]
−
|Moderate
+
|High/Moderate: ≥4 mg/day <br> Low/Minimal: <4 mg/day
 
|Minimal
 
|Minimal
 
|
 
|
 
|-
 
|-
 
|align="left" | [[Busulfan (Myleran)]] (oral)
 
|align="left" | [[Busulfan (Myleran)]] (oral)
−
|High/Moderate: =>4 mg/day<br>Low/Minimal: <4 mg/day
+
|High/Moderate: ≥4 mg/day<br>Low/Minimal: <4 mg/day
 
|
 
|
 
|NCCN did not further delineate between degrees of emetic potential  
 
|NCCN did not further delineate between degrees of emetic potential  
Line 97: Line 117:
 
|Low
 
|Low
 
|Low
 
|Low
 +
|
 +
|-
 +
|align="left" | [[Cabozantinib (Cometriq)]] (oral)
 +
|Low/Minimal
 +
|
 
|
 
|
 
|-
 
|-
Line 107: Line 132:
 
|Moderate
 
|Moderate
 
|Moderate
 
|Moderate
 +
|
 +
|-
 +
|align="left" | [[Carfilzomib (Kyprolis)]]
 +
|Low
 +
|
 
|
 
|
 
|-
 
|-
 
|align="left" | [[Carmustine (BiCNU)]]  
 
|align="left" | [[Carmustine (BiCNU)]]  
−
|High: >250 mg/m2<br>Moderate: <=250 mg/m2
+
|High: >250 mg/m2<br>Moderate: ≤250 mg/m2
 
|High
 
|High
 
|ASCO did not subclassify based on dose
 
|ASCO did not subclassify based on dose
Line 130: Line 160:
 
|-
 
|-
 
|align="left" | [[Cisplatin (Platinol)]]
 
|align="left" | [[Cisplatin (Platinol)]]
−
|High: >=50 mg/m2<br>Moderate: <50 mg/m2
 
 
|High
 
|High
−
|ASCO did not subclassify based on dose
+
|High
 +
|
 
|-
 
|-
 
|align="left" | [[Cladribine (Leustatin)]]
 
|align="left" | [[Cladribine (Leustatin)]]
Line 142: Line 172:
 
|Moderate
 
|Moderate
 
|Moderate
 
|Moderate
 +
|
 +
|-
 +
|align="left" | [[Crizotinib (Xalkori)]] (oral)
 +
|High/Moderate
 +
|
 
|
 
|
 
|-
 
|-
 
|align="left" | [[Cyclophosphamide (Cytoxan)]]  
 
|align="left" | [[Cyclophosphamide (Cytoxan)]]  
−
|High: >1500 mg/m2 or [[#Emetic_risk_of_chemotherapy|when given with certain anthracyclines]]<br>Moderate: <=1500 mg/m2
+
|High: >1500 mg/m2 or [[#Emetic_risk_of_chemotherapy|when given with certain anthracyclines]]<br>Moderate: ≤1500 mg/m2
−
|High: =>1500 mg/m2 or [[#Emetic_risk_of_chemotherapy|when given with anthracyclines]]<br>Moderate: <1500 mg/m2
+
|High: ≥1500 mg/m2 or [[#Emetic_risk_of_chemotherapy|when given with anthracyclines]]<br>Moderate: <1500 mg/m2
 
|
 
|
 
|-
 
|-
 
|align="left" | [[Cyclophosphamide (Cytoxan)]] (oral)
 
|align="left" | [[Cyclophosphamide (Cytoxan)]] (oral)
−
|High/Moderate: =>100 mg/m2/day<br>Low/Minimal: <100 mg/m2/day
+
|High/Moderate: ≥100 mg/m2/day<br>Low/Minimal: <100 mg/m2/day
 
|
 
|
 
|NCCN did not further delineate between degrees of emetic potential  
 
|NCCN did not further delineate between degrees of emetic potential  
 
|-
 
|-
 
|align="left" | [[Cytarabine (Cytosar)]]
 
|align="left" | [[Cytarabine (Cytosar)]]
−
|Moderate: >200 mg/m2<br>Low: 100-200 mg/m2
+
|Moderate: >200 mg/m2<br>Low: 100 to 200 mg/m2<br>Minimal: <100 mg/m2
−
|Moderate: >1000 mg/m2<br>Low: <=1000 mg/m2
+
|Moderate: >1000 mg/m2<br>Low: ≤1000 mg/m2
 +
|
 +
|-
 +
|align="left" | [[Dabrafenib (Tafinlar)]] (oral)
 +
|Low/Minimal
 +
|
 
|
 
|
 
|-
 
|-
Line 200: Line 240:
 
|-
 
|-
 
|align="left" | [[Doxorubicin (Adriamycin)]]
 
|align="left" | [[Doxorubicin (Adriamycin)]]
−
|High: >60 mg/m2 or when given with [[Cyclophosphamide (Cytoxan)]]<br>Moderate: <=60 mg/m2
+
|High: ≥60 mg/m2 or when given with [[Cyclophosphamide (Cytoxan)]]<br>Moderate: <60 mg/m2
 
|High when given with [[Cyclophosphamide (Cytoxan)]]<br>Moderate when used alone
 
|High when given with [[Cyclophosphamide (Cytoxan)]]<br>Moderate when used alone
 
|
 
|
Line 210: Line 250:
 
|-
 
|-
 
|align="left" | [[Epirubicin (Ellence)]]  
 
|align="left" | [[Epirubicin (Ellence)]]  
−
|High: >90 mg/m2 or when given with [[Cyclophosphamide (Cytoxan)]]<br>Moderate: <=90 mg/m2
+
|High: >90 mg/m2 or when given with [[Cyclophosphamide (Cytoxan)]]<br>Moderate: ≤90 mg/m2
 
|High when given with [[Cyclophosphamide (Cytoxan)]]<br>Moderate when used alone
 
|High when given with [[Cyclophosphamide (Cytoxan)]]<br>Moderate when used alone
 
|
 
|
Line 243: Line 283:
 
|
 
|
 
|NCCN did not further delineate between degrees of emetic potential  
 
|NCCN did not further delineate between degrees of emetic potential  
 +
|-
 +
|align="left" | [[Floxuridine (FUDR)]]
 +
|Low
 +
|
 +
|
 
|-
 
|-
 
|align="left" | [[Fludarabine (Fludara)]]
 
|align="left" | [[Fludarabine (Fludara)]]
Line 280: Line 325:
 
|-
 
|-
 
|align="left" | [[Ifosfamide (Ifex)]]  
 
|align="left" | [[Ifosfamide (Ifex)]]  
−
|High: >=10 g/m2 <br>Moderate: <10 g/m2
+
|High: ≥2 g/m2 per dose <br> Moderate: <2 g/m2 per dose
 
|Moderate
 
|Moderate
 
|ASCO did not subclassify based on dose
 
|ASCO did not subclassify based on dose
Line 290: Line 335:
 
|-
 
|-
 
|align="left" | [[Interferon alfa-2a (Roferon-A)]]
 
|align="left" | [[Interferon alfa-2a (Roferon-A)]]
−
|Moderate: >=10 million international units/m2<br>Low: >5, <10 million international units/m2<br>Minimal: <=5 million international units/m2
+
|Moderate: ≥10 million international units/m2<br>Low: >5, <10 million international units/m2<br>Minimal: ≤5 million international units/m2
 
|
 
|
 
|NCCN did not specify interferon alfa-2a vs. 2b
 
|NCCN did not specify interferon alfa-2a vs. 2b
 
|-
 
|-
 
|align="left" | [[Interferon alfa-2b (Intron-A)]]
 
|align="left" | [[Interferon alfa-2b (Intron-A)]]
−
|Moderate: >=10 million international units/m2<br>Low: >5, <10 million international units/m2<br>Minimal: <=5 million international units/m2
+
|Moderate: ≥10 million international units/m2<br>Low: >5, <10 million international units/m2<br>Minimal: ≤5 million international units/m2
 
|
 
|
 
|NCCN did not specify interferon alfa-2a vs. 2b
 
|NCCN did not specify interferon alfa-2a vs. 2b
Line 325: Line 370:
 
|-
 
|-
 
|align="left" | [[Lomustine (Ceenu)]] (oral)
 
|align="left" | [[Lomustine (Ceenu)]] (oral)
−
|High/Moderate
+
|High/Moderate (single day)
 
|
 
|
 
|single day; NCCN did not further delineate between degrees of emetic potential  
 
|single day; NCCN did not further delineate between degrees of emetic potential  
Line 350: Line 395:
 
|-
 
|-
 
|align="left" | [[Methotrexate (MTX)]]
 
|align="left" | [[Methotrexate (MTX)]]
−
|Moderate: >=250 mg/m2<br>Low: >50, <250 mg/m2<br>Minimal: <=50 mg/m2
+
|Moderate: ≥250 mg/m2<br>Low: >50, <250 mg/m2<br>Minimal: ≤50 mg/m2
 
|Low
 
|Low
 
|ASCO did not subclassify based on dose
 
|ASCO did not subclassify based on dose
Line 362: Line 407:
 
|Low
 
|Low
 
|Low
 
|Low
 +
|
 +
|-
 +
|align="left" | [[Mitotane (Lysodren)]] (oral)
 +
|High/Moderate
 +
|
 
|
 
|
 
|-
 
|-
Line 381: Line 431:
 
|align="left" | [[Ofatumumab (Arzzera)]]
 
|align="left" | [[Ofatumumab (Arzzera)]]
 
|Minimal
 
|Minimal
 +
|
 +
|
 +
|-
 +
|align="left" | [[Omacetaxine (Synribo)]]
 +
|Low
 
|
 
|
 
|
 
|
Line 431: Line 486:
 
|align="left" | [[Pentostatin (Nipent)]]
 
|align="left" | [[Pentostatin (Nipent)]]
 
|Low
 
|Low
 +
|
 +
|
 +
|-
 +
|align="left" | [[Pertuzumab (Perjeta)]]
 +
|Minimal
 +
|
 +
|
 +
|-
 +
|align="left" | [[Pomalidomide (Pomalyst)]] (oral)
 +
|Low/Minimal
 +
|
 +
|
 +
|-
 +
|align="left" | [[Ponatinib (Iclusig))]] (oral)
 +
|Low/Minimal
 
|
 
|
 
|
 
|
Line 443: Line 513:
 
|
 
|
 
|NCCN did not further delineate between degrees of emetic potential  
 
|NCCN did not further delineate between degrees of emetic potential  
 +
|-
 +
|align="left" | [[Regorafenib (Stivarga)]] (oral)
 +
|Low/Minimal
 +
|
 +
|
 
|-
 
|-
 
|align="left" | [[Rituximab (Rituxan)]]
 
|align="left" | [[Rituximab (Rituxan)]]
Line 451: Line 526:
 
|align="left" | [[Romidepsin (Istodax)]]
 
|align="left" | [[Romidepsin (Istodax)]]
 
|Low
 
|Low
 +
|
 +
|
 +
|-
 +
|align="left" | [[Ruxolitinib (Jakafi)]] (oral)
 +
|Low/Minimal
 
|
 
|
 
|
 
|
Line 475: Line 555:
 
|-
 
|-
 
|align="left" | [[Temozolmide (Temodar)]] (oral)
 
|align="left" | [[Temozolmide (Temodar)]] (oral)
−
|High/Moderate: >75 mg/m2/day<br>Low/Minimal: <=75 mg/m2/day
+
|High/Moderate: >75 mg/m2/day<br>Low/Minimal: ≤75 mg/m2/day
 
|
 
|
 
|NCCN did not further delineate between degrees of emetic potential  
 
|NCCN did not further delineate between degrees of emetic potential  
Line 508: Line 588:
 
|
 
|
 
|NCCN did not further delineate between degrees of emetic potential  
 
|NCCN did not further delineate between degrees of emetic potential  
 +
|-
 +
|align="left" | [[Trametinib (Mekinist)]] (oral)
 +
|Low/Minimal
 +
|
 +
|
 
|-
 
|-
 
|align="left" | [[Trastuzumab (Herceptin)]]
 
|align="left" | [[Trastuzumab (Herceptin)]]
Line 528: Line 613:
 
|
 
|
 
|NCCN did not further delineate between degrees of emetic potential  
 
|NCCN did not further delineate between degrees of emetic potential  
 +
|-
 +
|align="left" | [[Vemurafenib (Zelboraf)]] (oral)
 +
|Low/Minimal
 +
|
 +
|
 
|-
 
|-
 
|align="left" | [[Vinblastine (Velban)]]
 
|align="left" | [[Vinblastine (Velban)]]
Line 537: Line 627:
 
|Minimal
 
|Minimal
 
|Minimal
 
|Minimal
 +
|
 +
|-
 +
|align="left" | [[Vincristine liposomal (Marqibo)]]
 +
|Minimal
 +
|
 
|
 
|
 
|-
 
|-
Line 542: Line 637:
 
|Minimal
 
|Minimal
 
|Minimal
 
|Minimal
 +
|
 +
|-
 +
|align="left" | [[Vismodegib (Erivedge)]] (oral)
 +
|High/Moderate
 +
|
 
|
 
|
 
|-
 
|-
Line 548: Line 648:
 
|
 
|
 
|NCCN did not further delineate between degrees of emetic potential  
 
|NCCN did not further delineate between degrees of emetic potential  
 +
|-
 +
|align="left" | [[Ziv-aflibercept (Zaltrap)]]
 +
|Low
 +
|
 +
|
 
|-
 
|-
 
|}
 
|}
Line 563: Line 668:
 
*[[Ondansetron (Zofran)]] (choose one of the options below):
 
*[[Ondansetron (Zofran)]] (choose one of the options below):
 
**16-24 mg PO day 1
 
**16-24 mg PO day 1
−
**8-24 mg (max 32 mg/day)<ref name="ondansetron QTc">As of 6/28/2012, the once daily dose of ondansetron (Zofran) 32 mg is no longer recommended due to dose-dependent QTc prolongation.  The [http://us.gsk.com/products/assets/us_zofran.pdf Ondansetron (Zofran) package insert] recommends only a maximum of 16 mg per dose, which can be given as often as every 4 hours x up to 3 doses, as detailed in the 6/29/2012 [http://www.fda.gov/Drugs/DrugSafety/ucm310190.htm FDA Drug Safety Communication].</ref> IV day 1 (optional: may continue using on day 2-3)
+
**8-16 mg IV<ref name="ondansetron QTc">As of 6/28/2012, the once daily dose of ondansetron (Zofran) 32 mg is no longer recommended due to dose-dependent QTc prolongation.  The [http://us.gsk.com/products/assets/us_zofran.pdf Ondansetron (Zofran) package insert] recommends only a maximum of 16 mg per dose, which can be given as often as every 4 hours x up to 3 doses, as detailed in the 6/29/2012 [http://www.fda.gov/Drugs/DrugSafety/ucm310190.htm FDA Drug Safety Communication].</ref> IV day 1 (optional: may continue using on day 2-3)
 
*[[Palonosetron (Aloxi)]] (choose one of the options below):
 
*[[Palonosetron (Aloxi)]] (choose one of the options below):
 
**0.25 mg IV day 1
 
**0.25 mg IV day 1
Line 577: Line 682:
 
===Steroid===
 
===Steroid===
 
''Steroids contraindicated for use with interleukin-2 and interferon.''
 
''Steroids contraindicated for use with interleukin-2 and interferon.''
−
*If [[Aprepitant (Emend)]] 125 mg or [[Fosaprepitant (Emend for Injection)]] 115mg on day 1:  
+
*If [[Aprepitant (Emend)]] 125 mg or [[Fosaprepitant (Emend for Injection)]] 115 mg on day 1:  
 
**NCCN: [[Dexamethasone (Decadron)]] 12 mg PO/IV on day 1, then 8 mg PO once per day on days 2 to 4
 
**NCCN: [[Dexamethasone (Decadron)]] 12 mg PO/IV on day 1, then 8 mg PO once per day on days 2 to 4
 
**ASCO: [[Dexamethasone (Decadron)]] 12 mg PO/IV day 1, 8 mg PO/IV once per day on days 2 & 3 or 2 to 4
 
**ASCO: [[Dexamethasone (Decadron)]] 12 mg PO/IV day 1, 8 mg PO/IV once per day on days 2 & 3 or 2 to 4
Line 586: Line 691:
 
===Optional===
 
===Optional===
 
*[[Lorazepam (Ativan)]] 0.5-2 mg PO/IV/sublingual Q4-6H prn nausea on days 1 to 4  
 
*[[Lorazepam (Ativan)]] 0.5-2 mg PO/IV/sublingual Q4-6H prn nausea on days 1 to 4  
−
*H2 blocker or proton pump inhibitor
+
*[[:Category:H2-receptor antagonists|H2 blocker]] or [[:Category:Proton pump inhibitors|proton pump inhibitor]]
  
 
==Antiemetics for moderately emetogenic IV chemotherapy==
 
==Antiemetics for moderately emetogenic IV chemotherapy==
Line 601: Line 706:
 
*[[Ondansetron (Zofran)]] (choose one of the options below):
 
*[[Ondansetron (Zofran)]] (choose one of the options below):
 
**16 to 24 mg PO day 1
 
**16 to 24 mg PO day 1
−
**8 to 24 mg (max 32 mg/day)<ref name="[[Ondansetron (Zofran)]] QTc"></ref> IV day 1
+
**8 to 16 mg IV day 1<ref name="ondansetron QTc"></ref> IV day 1
 
*[[Palonosetron (Aloxi)]] (choose one of the options below):
 
*[[Palonosetron (Aloxi)]] (choose one of the options below):
 
**0.25 mg IV day 1
 
**0.25 mg IV day 1
Line 614: Line 719:
 
*[[Aprepitant (Emend)]] 125 mg PO day 1 or [[Fosaprepitant (Emend for Injection)]] 115 mg IV day 1
 
*[[Aprepitant (Emend)]] 125 mg PO day 1 or [[Fosaprepitant (Emend for Injection)]] 115 mg IV day 1
 
*[[Lorazepam (Ativan)]] 0.5 to 2 mg PO/IV/sublingual Q4 to 6H prn nausea days 1 to 4  
 
*[[Lorazepam (Ativan)]] 0.5 to 2 mg PO/IV/sublingual Q4 to 6H prn nausea days 1 to 4  
−
*H2 blocker or proton pump inhibitor
+
*[[:Category:H2-receptor antagonists|H2 blocker]] or [[:Category:Proton pump inhibitors|proton pump inhibitor]]
  
 
===Day 2 and 3===
 
===Day 2 and 3===
Line 629: Line 734:
 
**8 mg PO BID on days 2 & 3
 
**8 mg PO BID on days 2 & 3
 
**16 mg PO once per day on days 2 & 3
 
**16 mg PO once per day on days 2 & 3
−
**8 mg IV (up to 32 mg/day<ref name="[[Ondansetron (Zofran)]] QTc"></ref>) days 2 to 3
+
**8 to 16 mg IV <ref name="ondansetron QTc"></ref> days 2 to 3
  
 
====Steroid====
 
====Steroid====
Line 640: Line 745:
 
====Optional====
 
====Optional====
 
*[[Lorazepam (Ativan)]] 0.5-2 mg PO/IV/sublingual Q4-6H prn nausea
 
*[[Lorazepam (Ativan)]] 0.5-2 mg PO/IV/sublingual Q4-6H prn nausea
−
*H2 blocker or proton pump inhibitor
+
*[[:Category:H2-receptor antagonists|H2 blocker]] or [[:Category:Proton pump inhibitors|proton pump inhibitor]]
  
 
==Antiemetics for highly to moderately emetogenic PO chemotherapy==
 
==Antiemetics for highly to moderately emetogenic PO chemotherapy==
Line 653: Line 758:
 
===Optional===
 
===Optional===
 
*[[Lorazepam (Ativan)]] 0.5-2 mg PO/IV/sublingual Q4-6H prn nausea on days 1 to 4  
 
*[[Lorazepam (Ativan)]] 0.5-2 mg PO/IV/sublingual Q4-6H prn nausea on days 1 to 4  
−
*H2 blocker or proton pump inhibitor
+
*[[:Category:H2-receptor antagonists|H2 blocker]] or [[:Category:Proton pump inhibitors|proton pump inhibitor]]
  
 
==Antiemetics for low emetic risk IV chemotherapy==
 
==Antiemetics for low emetic risk IV chemotherapy==
Line 665: Line 770:
 
===Optional===
 
===Optional===
 
*[[Lorazepam (Ativan)]] 0.5-2 mg PO/IV/sublingual Q4-6H prn nausea days 1-4  
 
*[[Lorazepam (Ativan)]] 0.5-2 mg PO/IV/sublingual Q4-6H prn nausea days 1-4  
−
*H2 blocker or proton pump inhibitor
+
*[[:Category:H2-receptor antagonists|H2 blocker]] or [[:Category:Proton pump inhibitors|proton pump inhibitor]]
  
 
==Minimal emetic risk chemotherapy==
 
==Minimal emetic risk chemotherapy==
Line 681: Line 786:
 
===Optional===
 
===Optional===
 
*[[Lorazepam (Ativan)]] 0.5-2 mg PO/IV/sublingual Q4-6H prn nausea days 1-4  
 
*[[Lorazepam (Ativan)]] 0.5-2 mg PO/IV/sublingual Q4-6H prn nausea days 1-4  
−
*H2 blocker or proton pump inhibitor
+
*[[:Category:H2-receptor antagonists|H2 blocker]] or [[:Category:Proton pump inhibitors|proton pump inhibitor]]
  
 
===If continued nausea/vomiting===
 
===If continued nausea/vomiting===

Revision as of 08:57, 2 March 2015

Adapted from the NCCN[1] and ASCO guidelines.[2][3][4]

Emetic risk of chemotherapy

Hint: You can sort the table by clicking on the boxes containing arrows at the top of each column.
All drugs are IV route unless otherwise specified.

NCCN categories of emetic risk:

  • High: >90% frequency of emesis
  • Moderate: 30-90% frequency of emesis
  • Low: 10-30% frequency of emesis
  • Minimal: <10% frequency of emesis

ASCO guidelines say that in cases of combination chemotherapy regimens, patients should be given antiemetics that are recommended for the individual medication with the highest emetic risk. The exception is with anthracycline and Cyclophosphamide (Cytoxan) combinations as described below.

Drug NCCN emetogenic potential ASCO emetogenic potential Comment
Ado-trastuzumab emtansine (Kadcyla) Low
Anthracycline (see differences between NCCN & ASCO) & Cyclophosphamide (Cytoxan) combination chemotherapy High (Doxorubicin (Adriamycin) or Epirubicin (Ellence) with Cyclophosphamide (Cytoxan)) High (Daunorubicin (Cerubidine), Doxorubicin (Adriamycin), Epirubicin (Ellence), or Idarubicin (Idamycin) with Cyclophosphamide (Cytoxan))
Aldesleukin (Proleukin) Moderate: >12 to 15 million international units/m2
Low: ≤12 million international units/m2
Alemtuzumab (Campath) Minimal Moderate
Altretamine (Hexalen) (oral) High/Moderate NCCN did not further delineate between degrees of emetic potential
Amifostine (Ethyol) Moderate: >300 mg/m2
Low: ≤300 mg
Arsenic trioxide (Trisenox) Moderate
Asparaginase (Elspar) Minimal
Axitinib (Inlyta) (oral) Low/Minimal
Azacitidine (Vidaza) Moderate Moderate
Bendamustine (Treanda) Moderate Moderate
Bevacizumab (Avastin) Minimal Minimal
Bexarotene (Targretin) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Bleomycin (Blenoxane) Minimal Minimal
Bortezomib (Velcade) Minimal Low
Bosutinib (Bosulif) (oral) Low/Minimal
Brentuximab vedotin (Adcetris) Low
Busulfan (Myleran) High/Moderate: ≥4 mg/day
Low/Minimal: <4 mg/day 		Minimal
Busulfan (Myleran) (oral) High/Moderate: ≥4 mg/day
Low/Minimal: <4 mg/day 		NCCN did not further delineate between degrees of emetic potential
Cabazitaxel (Jevtana) Low Low
Cabozantinib (Cometriq) (oral) Low/Minimal
Capecitabine (Xeloda) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Carboplatin (Paraplatin) Moderate Moderate
Carfilzomib (Kyprolis) Low
Carmustine (BiCNU) High: >250 mg/m2
Moderate: ≤250 mg/m2 		High ASCO did not subclassify based on dose
Catumaxomab (Removab) Low
Cetuximab (Erbitux) Minimal Minimal
Chlorambucil (Leukeran) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Cisplatin (Platinol) High High
Cladribine (Leustatin) Minimal Minimal
Clofarabine (Clolar) Moderate Moderate
Crizotinib (Xalkori) (oral) High/Moderate
Cyclophosphamide (Cytoxan) High: >1500 mg/m2 or when given with certain anthracyclines
Moderate: ≤1500 mg/m2 		High: ≥1500 mg/m2 or when given with anthracyclines
Moderate: <1500 mg/m2
Cyclophosphamide (Cytoxan) (oral) High/Moderate: ≥100 mg/m2/day
Low/Minimal: <100 mg/m2/day 		NCCN did not further delineate between degrees of emetic potential
Cytarabine (Cytosar) Moderate: >200 mg/m2
Low: 100 to 200 mg/m2
Minimal: <100 mg/m2 		Moderate: >1000 mg/m2
Low: ≤1000 mg/m2
Dabrafenib (Tafinlar) (oral) Low/Minimal
Dacarbazine (DTIC) High High
Dactinomycin (Cosmegen) Moderate High
Dasatinib (Sprycel) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Daunorubicin (Cerubidine) Moderate High when given with Cyclophosphamide (Cytoxan)
Moderate when used alone
Decitabine (Dacogen) Minimal
Denileukin diftitox (Ontak) Minimal
Dexrazoxane (Zinecard) Minimal
Docetaxel (Taxotere) Low Low
Doxorubicin (Adriamycin) High: ≥60 mg/m2 or when given with Cyclophosphamide (Cytoxan)
Moderate: <60 mg/m2 		High when given with Cyclophosphamide (Cytoxan)
Moderate when used alone
Doxorubicin liposomal (Doxil) Low Low
Epirubicin (Ellence) High: >90 mg/m2 or when given with Cyclophosphamide (Cytoxan)
Moderate: ≤90 mg/m2 		High when given with Cyclophosphamide (Cytoxan)
Moderate when used alone
Eribulin (Halaven) Low
Erlotinib (Tarceva) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Estramustine (Emcyt) (oral) High/Moderate NCCN did not further delineate between degrees of emetic potential
Etoposide (Vepesid) Low Low
Etoposide (Vepesid) (oral) High/Moderate NCCN did not further delineate between degrees of emetic potential
Everolimus (Afinitor) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Floxuridine (FUDR) Low
Fludarabine (Fludara) Minimal Minimal
Fludarabine (Fludara) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Fluorouracil (5-FU) Low Low
Gefitinib (Iressa) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Gemcitabine (Gemzar) Low Low
Hydroxyurea (Hydrea) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Idarubicin (Idamycin) Moderate High when given with Cyclophosphamide (Cytoxan)
Moderate when used alone
Ifosfamide (Ifex) High: ≥2 g/m2 per dose
Moderate: <2 g/m2 per dose 		Moderate ASCO did not subclassify based on dose
Imatinib (Gleevec) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Interferon alfa-2a (Roferon-A) Moderate: ≥10 million international units/m2
Low: >5, <10 million international units/m2
Minimal: ≤5 million international units/m2 		NCCN did not specify interferon alfa-2a vs. 2b
Interferon alfa-2b (Intron-A) Moderate: ≥10 million international units/m2
Low: >5, <10 million international units/m2
Minimal: ≤5 million international units/m2 		NCCN did not specify interferon alfa-2a vs. 2b
Ipilimumab (Yervoy) Minimal
Irinotecan (Camptosar) Moderate Moderate
Ixabepilone (Ixempra) Low Low
Lapatinib (Tykerb) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Lenalidomide (Revlimid) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Lomustine (Ceenu) (oral) High/Moderate (single day) single day; NCCN did not further delineate between degrees of emetic potential
Mechlorethamine (Mustargen) High High
Melphalan (Alkeran) Moderate
Melphalan (Alkeran) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Mercaptopurine (Purinethol) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Methotrexate (MTX) Moderate: ≥250 mg/m2
Low: >50, <250 mg/m2
Minimal: ≤50 mg/m2 		Low ASCO did not subclassify based on dose
Methotrexate (MTX) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Mitomycin (Mutamycin) Low Low
Mitotane (Lysodren) (oral) High/Moderate
Mitoxantrone (Novantrone) Low Low
Nelarabine (Arranon) Minimal
Nilotinib (Tasigna) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Ofatumumab (Arzzera) Minimal
Omacetaxine (Synribo) Low
Oxaliplatin (Eloxatin) Moderate Moderate
Paclitaxel (Taxol) Low Low
Paclitaxel, nanoparticle albumin-bound (Abraxane) Low
Panitumumab (Vectibix) Minimal
Pazopanib (Votrient) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Peg-asparginase (Oncaspar) Minimal
Peginterferon alfa-2a (Pegasys) Minimal NCCN did not specify interferon alfa-2a vs. 2b
Peginterferon alfa-2b (PegIntron) Minimal NCCN did not specify interferon alfa-2a vs. 2b
Pemetrexed (Alimta) Low Low
Pentostatin (Nipent) Low
Pertuzumab (Perjeta) Minimal
Pomalidomide (Pomalyst) (oral) Low/Minimal
Ponatinib (Iclusig)) (oral) Low/Minimal
Pralatrexate (Folotyn) Low Minimal
Procarbazine (Matulane) (oral) High/Moderate NCCN did not further delineate between degrees of emetic potential
Regorafenib (Stivarga) (oral) Low/Minimal
Rituximab (Rituxan) Minimal Minimal
Romidepsin (Istodax) Low
Ruxolitinib (Jakafi) (oral) Low/Minimal
Sorafenib (Nexavar) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Streptozocin (Zanosar) High High
Sunitinib (Sutent) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Temozolmide (Temodar) Moderate
Temozolmide (Temodar) (oral) High/Moderate: >75 mg/m2/day
Low/Minimal: ≤75 mg/m2/day 		NCCN did not further delineate between degrees of emetic potential
Temsirolimus (Torisel) Minimal Low
Thalidomide (Thalomid) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Thioguanine (Tabloid) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Thiotepa (Thioplex) Low
Topotecan (Hycamtin) Low Low
Topotecan (Hycamtin) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Trametinib (Mekinist) (oral) Low/Minimal
Trastuzumab (Herceptin) Minimal Low
Tretinoin (Vesanoid) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Valrubicin (Valstar) Minimal
Vandetanib (Caprelsa) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Vemurafenib (Zelboraf) (oral) Low/Minimal
Vinblastine (Velban) Minimal Minimal
Vincristine (Oncovin) Minimal Minimal
Vincristine liposomal (Marqibo) Minimal
Vinorelbine (Navelbine) Minimal Minimal
Vismodegib (Erivedge) (oral) High/Moderate
Vorinostat (Zolinza) (oral) Low/Minimal NCCN did not further delineate between degrees of emetic potential
Ziv-aflibercept (Zaltrap) Low

Antiemetics for highly emetogenic IV chemotherapy

Select one option from each class:

Serotonin (5-HT3) antagonist

  • Dolasetron (Anzemet) 100 mg PO day 1
  • Granisetron (Kytril) (choose one of the options below):
    • 2 mg PO day 1
    • 1 mg PO BID day 1
    • 0.01 mg/kg (max 1mg) IV day 1
    • transdermal patch as 3.1 mg/24H patch (containing 34.3 mg granisetron total dose) placed ~24-48 hours before the first dose of chemotherapy. May use patch up to 7 days.
  • Ondansetron (Zofran) (choose one of the options below):
    • 16-24 mg PO day 1
    • 8-16 mg IV[5] IV day 1 (optional: may continue using on day 2-3)
  • Palonosetron (Aloxi) (choose one of the options below):
    • 0.25 mg IV day 1
    • 0.5 mg PO day 1
  • Ramosetron 0.3mg IV day 1
  • Tropisetron 5 mg PO/IV day 1

Neurokinin 1 antagonist

Steroid

Steroids contraindicated for use with interleukin-2 and interferon.

Optional

Antiemetics for moderately emetogenic IV chemotherapy

Day 1

Select one option from each class on day 1:

Serotonin (5-HT3) antagonist

Note: NCCN lists all of the below as potential options, whereas ASCO only lists Palonosetron (Aloxi). Palonosetron (Aloxi) is preferred by the NCCN.

  • Dolasetron (Anzemet) 100 mg PO day 1
  • Granisetron (Kytril) (choose one of the options below):
    • 2 mg PO day 1
    • 1 mg PO BID day 1
    • 0.01 mg/kg (max 1mg) IV day 1
    • transdermal patch as 3.1 mg/24H patch (containing 34.3 mg Granisetron (Kytril) total dose) placed ~24 to 48 hours before the first dose of chemotherapy. May use patch up to 7 days.
  • Ondansetron (Zofran) (choose one of the options below):
    • 16 to 24 mg PO day 1
    • 8 to 16 mg IV day 1[5] IV day 1
  • Palonosetron (Aloxi) (choose one of the options below):
    • 0.25 mg IV day 1
    • 0.5 mg PO day 1

Steroid

Steroids contraindicated for use with interleukin-2 and interferon.

Optional

Day 2 and 3

ASCO only recommends Dexamethasone (Decadron), whereas NCCN allows you to choose any one class of medication to use: either a serotonin (5-HT3) antagonist, or steroid, or neurokinin 1 antagonist +/- steroid.

Serotonin (5-HT3) antagonist

  • Dolasetron (Anzemet) 100 mg PO daily
  • Granisetron (Kytril) (choose one of the options below):
    • 1 to 2 mg PO once per day on days 2 & 3
    • 1 mg PO BID on days 2 & 3
    • 0.01 mg/kg (max 1mg) IV on days 2 & 3
    • continued use of 3.1 mg/24H transdermal patch
  • Ondansetron (Zofran) (choose one of the options below):
    • 8 mg PO BID on days 2 & 3
    • 16 mg PO once per day on days 2 & 3
    • 8 to 16 mg IV [5] days 2 to 3

Steroid

Steroids contraindicated for use with interleukin-2 and interferon.

Neurokinin 1 antagonist +/- steroid if NK-1 used on day 1

Optional

Antiemetics for highly to moderately emetogenic PO chemotherapy

These are NCCN recommendations only. ASCO did not provide separate recommendations for PO vs. IV chemotherapy.
Start before chemotherapy and continue once per day:

Serotonin (5-HT3) antagonist

Optional

Antiemetics for low emetic risk IV chemotherapy

Repeat once per day for chemotherapy regimens that last more than one day. ASCO only recommends Dexamethasone (Decadron), whereas NCCN allows you to choose any one medication to use: either Dexamethasone (Decadron), metoclopramide, or prochlorperazine.

Optional

Minimal emetic risk chemotherapy

  • No routine prophylaxis

Antiemetics for low to minimal emetic risk PO chemotherapy

  • use antiemetics prn first

If nausea/vomiting

Choose one of the medications below to start before chemotherapy and continue once per day:

Optional

If continued nausea/vomiting

Use serotonin (5-HT3) antagonist:

Breakthrough antinausea treatment

Use a medication from a different drug class from the current regimen as a prn medication.

Benzodiazepine

Cannabinoid

Miscellaneous

Phenothiazine

Serotonin 5-HT3 antagonist

Steroid

Steroids contraindicated for use with interleukin-2 and interferon.

Anticipatory nausea/vomiting

  • Prevent anticipation by optimizing antiemetic therapy for every cycle of chemotherapy
  • Behavioral therapy
    • Relaxation/systemic desensitization
    • Hypnosis/guided imagery
    • Music therapy
  • Acupuncture/acupressure
  • Alprazolam (Xanax) 0.5-2 mg PO TID starting the night before treatment
  • Lorazepam (Ativan) 0.5-2 mg PO the night before and the morning of treatment

Reference

  1. ↑ NCCN antiemesis guidelines version 2.2014
  2. ↑ Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update (2011)
  3. ↑ ASCO 2011 antiemetics guideline PDF
  4. ↑ ASCO 2011 antiemetics table
  5. ↑ 5.0 5.1 5.2 As of 6/28/2012, the once daily dose of ondansetron (Zofran) 32 mg is no longer recommended due to dose-dependent QTc prolongation. The Ondansetron (Zofran) package insert recommends only a maximum of 16 mg per dose, which can be given as often as every 4 hours x up to 3 doses, as detailed in the 6/29/2012 FDA Drug Safety Communication.
Retrieved from "https://hemonc.org/w/index.php?title=Antiemesis&oldid=7449"